Skip to main content

Posts

Showing posts with the label inflammation

Misunderstanding of ATP Involvement in Stages of Inflammation | Chapter 4 | New Visions in Medicine and Medical Science Vol. 4

  Inflammation is the description of the metabolic imbalance in any tissue describing the different three stages till it ends in the development of scarring. Inflammation starts with a changed relationship of ATP/ADP. Here, the different stages of inflammation and the ATP levels are investigated. But this view means to accept that ATP is not a danger signal as commonly reported,1,2,3,4but instead ATP is necessary in signaling homeostasis in the capillary system and tissues. Even if some of the references are seemingly old, they are still valid and newer publications promote the former misinterpretations. Author(s) Details: Gerd Wasser, Prof. H. C. Henan University, Kaifeng, PR China and Franz-Marc-Str. 12, Neukirchen-Vluyn, Deutschland, 47506, Germany. Please see the link here: https://stm.bookpi.org/NVMMS-V4/article/view/14000

The Inflammasomes: Revamping Periodontal Pathogenesis | Chapter 3 | New Frontiers in Medicine and Medical Research Vol. 7

The discovery of inflammasomes, which are thought to govern the host immuno-inflammatory responses, has baffled the medical community recently. They are thought to serve a variety of purposes throughout the process, many of which are still unknown. Certain sensor proteins have been found to be essential for the assembly of inflammasomes in response to microbial components known as PAMPs (pathogen associated molecular patterns) or endogenous chemicals known as DAMPs (damage associated molecular patterns). Inflammasomes have been shown to activate in two phases in the majority of cases. Furthermore, according to study, this involves a variety of sensor protein families that have a role in the development of a variety of diseases, including periodontal disease, via a variety of pathways. As a result, this piece of information allows us to go deeper and look for novel targets to modify host responses to microbial challenges. Author (S) Details Nazreen Ansari Department of Periodontic...

Determination of High Sensitivity C-Reactive Protein in Metabolic Syndrome | Chapter 12 | New Frontiers in Medicine and Medical Research Vol. 5

Background: If a person has metabolic syndrome, their risk of cardiovascular disease and type 2 diabetes mellitus is greatly elevated. In India, obesity and type 2 diabetes have become epidemics. Low-grade systemic inflammation characterises metabolic syndrome, which is a pro-inflammatory disease. C-reactive protein (CRP), a biomarker, is a reliable sign of chronic systemic inflammation. Higher levels of high sensitivity C-reactive protein (Hs-crp) have been associated to metabolic syndrome and its components, and can help predict future cardiovascular events. The following are the goals of the research: 1) The link between metabolic syndrome and high-sensitivity C reactive protein 2)An investigation of high-sensitivity C reactive protein as a surrogate measure of chronic inflammation in the metabolic syndrome. Methods and Materials The participants in this cross-sectional study included 50 patients with metabolic syndrome aged 18 and up, as well as 50 age and sex matched controls who ...

Phospholipase A2 Inhibition and Antiinflammatory Activity of F4 Fraction of Total Ethereal Leaf Extract of Annona senegalensis Pers. (Annonaceae) | Chapter 02 | New Insights on Chemical Research Vol. 1

Annona senegalensis Pers. (Annonaceae) is a plant which is used in african traditional medicine for the treatment of various diseases. This study aimed to investigate the analgesic and anti-inflammatory activity of total ethereal leaf extract fractions of A. senegalensis. Compounds of methanolic fractions of ethereal leaf extract of A. senegalensis were separated by gel sephadex chromatography, in five fractions (F1, F2, F3, F4, F5). Experiments were performed in acetic acid-induced contortions in mice, carrageenan rat paw edema and phospholipase A2 inhibitory test. The methanolic fraction of total ethereal leaf extract (10 mg/kg, per os) significantly prevented the carrageenan inflammatory edema. The variation of edema is 22.31 ± 3.35%, 49.66 ± 13.50%, 52.10 ± 10 .02% respectively at T1h, T3h and T5h. The increased edema after oral administration of F4 fraction administered at 300 µg/kg and 1 mg/kg per os is respectively 52.77 ± 7.36% and 33.81 ± 6.94%. The variation of edema in be...

TNF-α Inhibitor Treatment for Crohn’s Disease: Comparative Review of Post Therapy Malignancy between Infliximab and Adalimumab | Chapter 08 | Modern Advances in Pharmaceutical Research Vol. 2

The association between chronic inflammatory disease and cancer has been well established through years of research. In corollary, progressive resistance to chimeric monoclonal antibodies has been reported in literature. The purpose of this investigation was to establish the overall trend of the chimeric monoclonal antibody (Infliximab) failure compared with human monoclonal antibody (Adalimumab). It was opined that this failure may result in subclinical yet cancer-inducing inflammation that could be measurable in patient populations undergoing the therapy by examining cancer prevalence. An overall trend of increased incidence of new malignancy in patient populations on Infliximab compared with Adalimumab was confirmed from the literature reviewed. There was also a significant trend of developing Gastrointestinal (GI) related cancer in patients on Infliximab, which corresponds with the majority of the progression process in Crohn’s disease. It was opined that future observations in ...